Development and Characterization of Nanoliposomal Hydroxyurea Against Bt-474 Breast Cancer Cells

Development and Characterization of Nanoliposomal Hydroxyurea Against Bt-474 Breast Cancer Cells Publisher

Akbari A^{1, 2} ; Akbarzadeh A² ; Tehrani MR¹ ; Cohan RA² ; Chiani M² ; Mehrabi MR²

Show Affiliations

1. Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Nanobiotechnology, Pasteur Institute of Iran, Tehran, Iran

Source: Advanced Pharmaceutical Bulletin Published:2020

Abstract

Purpose: Hydroxyurea (HU) is a well-known chemotherapy drug with several side effects which limit its clinical application. This study was conducted to improve its therapeutic efficiency against breast cancer using liposomes as FDA-approved drug carriers. Methods: PEGylated nanoliposomes-containing HU (NL-HU) were made via a thin-film hydration method, and assessed in terms of zeta potential, size, morphology, release, stability, cellular uptake, and cytotoxicity. The particle size and zeta potential of NL-HU were specified by zeta-sizer. The drug release from liposomes was assessed by dialysis diffusion method. Cellular uptake was evaluated by flow cytometry. The cytotoxicity was designated by methyl thiazolyl diphenyl-tetrazolium bromide (MTT) test. Results: The size and zeta value of NL-HU were gotten as 85 nm and-27 mV, respectively. NL-HU were spherical.NL-HU vesicles were detected to be stable for two months. The slow drug release and Weibull kinetic model were obtained. Liposomes considerably enhanced the uptake of HU into BT-474 human breast cancer cells. The cytotoxicity of NL-HU on BT-474 cells was found to be significantly more than that of free HU. Conclusion: The results confirmed these PEGylated nanoliposomes containing drug are potentially suitable against in vitro model of breast cancer. © 2020 The Author (s).

Related Docs

View other Related Docs

1. Preparation and Evaluation of a Liposome Drug Delivery System in Cancer Treatment in Vitro, Journal of Nanostructures (2020)

2. What We Need to Know About Liposomes As Drug Nanocarriers: An Updated Review, Advanced Pharmaceutical Bulletin (2023)

3. Nanoliposome Encapsulated Anesthetics for Local Anesthesia Application, Biomedicine and Pharmacotherapy (2017)

4. General Justification in Terms of Effectiveness and Toxicities for the Use of Nanocarriers, Journal of Nanoparticle Research (2023)

5. Methylprednisolone Acetate-Eudragit® Rs100 Electrospuns: Preparation and Physicochemical Characterization, Artificial Cells# Nanomedicine and Biotechnology (2016)

6. Ignoring the Modeling Approaches: Towards the Shadowy Paths in Nanomedicine, Journal of Controlled Release (2018)

7. Liposomes: Structure, Biomedical Applications, and Stability Parameters With Emphasis on Cholesterol, Frontiers in Bioengineering and Biotechnology (2021)

8. Enhancing Sirna Cancer Therapy: Multifaceted Strategies With Lipid and Polymer-Based Carrier Systems, International Journal of Pharmaceutics (2024)

Experts (# of related papers)

View all Related Experts

Rassoul Dinarvand (3)

Fatemeh Atyabi (2)

Style	Citing Format
MLA	Akbari A, et al.. "Development and Characterization of Nanoliposomal Hydroxyurea Against Bt-474 Breast Cancer Cells." Advanced Pharmaceutical Bulletin, vol. 10, no. 1, 2020, pp. 39-45.
APA	Akbari A, Akbarzadeh A, Tehrani MR, Cohan RA, Chiani M, Mehrabi MR (2020). Development and Characterization of Nanoliposomal Hydroxyurea Against Bt-474 Breast Cancer Cells. Advanced Pharmaceutical Bulletin, 10(1), 39-45.
Chicago	Akbari A, Akbarzadeh A, Tehrani MR, Cohan RA, Chiani M, Mehrabi MR. "Development and Characterization of Nanoliposomal Hydroxyurea Against Bt-474 Breast Cancer Cells." Advanced Pharmaceutical Bulletin 10, no. 1 (2020): 39-45.
Harvard	Akbari A et al. (2020) 'Development and Characterization of Nanoliposomal Hydroxyurea Against Bt-474 Breast Cancer Cells', Advanced Pharmaceutical Bulletin, 10(1), pp. 39-45.
Vancouver	Akbari A, Akbarzadeh A, Tehrani MR, Cohan RA, Chiani M, Mehrabi MR. Development and Characterization of Nanoliposomal Hydroxyurea Against Bt-474 Breast Cancer Cells. Advanced Pharmaceutical Bulletin. 2020;10(1):39-45.
BibTex	@article{ author = {Akbari A and Akbarzadeh A and Tehrani MR and Cohan RA and Chiani M and Mehrabi MR}, title = {Development and Characterization of Nanoliposomal Hydroxyurea Against Bt-474 Breast Cancer Cells}, journal = {Advanced Pharmaceutical Bulletin}, volume = {10}, number = {1}, pages = {39-45}, year = {2020} }
RIS	TY - JOUR AU - Akbari A AU - Akbarzadeh A AU - Tehrani MR AU - Cohan RA AU - Chiani M AU - Mehrabi MR TI - Development and Characterization of Nanoliposomal Hydroxyurea Against Bt-474 Breast Cancer Cells JO - Advanced Pharmaceutical Bulletin VL - 10 IS - 1 SP - 39 EP - 45 PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract